As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?

Novo Nordisk is aggressively pursuing over 130 lawsuits against smaller pharmacies and telehealth providers for selling compounded versions of its weight-loss drug Wegovy, yet Hims & Hers, a major player continuing to offer cheaper copies, remains conspicuously absent from these actions. This puzzles investors, especially given Novo's prior IP accusations against Hims. Legal experts suggest Novo's current strategy against smaller entities may be a tactical move to test legal interpretations of compounding laws or pressure larger players, though a past business relationship between Novo and Hims complicates potential future litigation.

Analysis

Novo Nordisk is engaged in an expansive legal campaign to protect its highly profitable weight-loss drug, Wegovy, having filed over 130 lawsuits in 40 U.S. states against pharmacies and telehealth providers selling compounded copies. However, a conspicuous gap in this strategy is the absence of litigation against Hims & Hers, a high-profile telehealth company that continues to sell lower-priced compounded versions, which is noted to contribute to weaker sales growth for Novo. This inaction has generated uncertainty among investors, as noted by Barclays, especially since Novo previously accused Hims of intellectual property violations. The core of the dispute rests on the ambiguous interpretation of U.S. compounding laws; Hims contends its personalized dosing remains legal, a claim that legal experts state is untested in courts. Legal strategists suggest Novo's current lawsuits against smaller entities could be a deliberate tactic, serving as a "shot across the bow" to pressure larger players or as a way to test legal arguments and set precedents before a potential major confrontation. The situation is further complicated by a prior business relationship between Novo and Hims, which experts believe could make a future lawsuit more difficult for Novo to pursue.

Key Decisions for Investors

• Investors in Novo Nordisk should monitor the outcomes of its current litigation against smaller firms, as favorable rulings could strengthen its position and signal an impending, more impactful lawsuit against larger players like Hims.
• For Hims & Hers investors, the primary risk is legal and regulatory; the absence of a lawsuit from Novo provides a temporary reprieve, but any change in Novo's legal strategy or a stricter FDA interpretation of compounding laws presents a significant threat to a core revenue stream.
• The unresolved legal status of compounded GLP-1 drugs is a key overhang for the telehealth and pharmaceutical sectors, and the eventual court interpretations will set a critical precedent for intellectual property rights versus compounded medicine.